Formula Systems Files Annual Report on Form 20-F for the Year Ended December 31, 2024
OR YEHUDA, Israel, May 19, 2025 (GLOBE NEWSWIRE) — Formula Systems (1985) Ltd. (Nasdaq and TASE: FORTY) ('Formula' or the 'Company'), a global information technology group engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the 'SEC') on Wednesday, May 14 2025. The annual report on Form 20-F, which contains Formula's audited annual financial statements for 2024, can be accessed on the SEC's website at http://www.sec.gov, as well as via the Company's investor relations website at https://www.formulasystems.com/en/financial-reports.
The Company will deliver a hard copy of its 2024 annual report on Form 20-F, including its complete audited financial statements, free of charge, to its shareholders upon request to Asaf Berenstin, Chief Financial Officer, at [email protected].
About Formula
Formula, whose ordinary shares are traded on the Tel-Aviv Stock Exchange and ADSs are traded on the Nasdaq Global Select Market, is a global information technology holding company engaged, through its subsidiaries and affiliates, in providing software consulting services and computer-based business solutions and developing proprietary software products.
To learn more about Formula, visit www.formulasystems.com.
Press Contact:
Formula Systems (1985) Ltd.+972-3-5389305
[email protected]
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run.
Key Points Palantir Technologies now ranks in the top 25 of the most valuable companies in the world. Its Artificial Intelligence Platform (AIP) is wildly popular for commercial and government clients. 10 stocks we like better than Palantir Technologies › There are probably few investors out there who are more satisfied than those who bought Palantir Technologies (NASDAQ: PLTR) stock early in its run. The artificial intelligence (AI) company is blowing other stocks out of the water these days, with its stock up 478% in the last year and more than doubling in 2025. Palantir is now one of the world's top 25 most valuable companies, ahead of such blue chip names as Procter & Gamble and Bank of America. Palantir's run is fueled by the adaptation of its Artificial Intelligence Platform (AIP) by government and commercial clients, fueling dramatic growth in both revenue and earnings. And with Palantir set to report second-quarter earnings on Aug. 4, there are plenty of reasons to believe that this run is far from over. How Palantir is making money Palantir already had two AI-powered platforms. Its Gotham platform is prized by governments and defense agencies to gather information from multiple sources, identify targets, and make real-time assessments to provide insights about battlefield situations. Palantir is recognized for helping the U.S. military track down 9/11 mastermind Osama bin Laden in 2011. Then you have the Foundry platform used by Palantir's commercial clients. Foundry helps clients manage supply chains and inventory, automate workflows, and optimize operations. The AIP platform made both of these powerful tools better and easier to use because AIP allows users to make detailed queries, and then it generates responses using generative AI. And the results are evident in the massive gains the company is seeing: Since rolling out AIP in April 2023, Palantir's revenues have gone through the roof. Year Revenue Profit (Loss) Earnings per Share 2021 $1.54 billion ($520.3 million) ($0.27) 2022 $1.90 billion ($161.2 million) ($0.18) 2023 $2.22 billion $217.3 million $0.10 2024 $2.86 billion $467.9 million $0.21 2025 (projected) $3.90 billion Image source: Palantir Technologies. In the first quarter of 2025, the company reported revenue of $884 million, up 39% from a year ago. U.S. commercial revenue jumped 71% from a year ago to $255 million, and U.S. government revenue was up 45% from a year ago to $373 million. The stock is by far outperforming the biggest companies on the planet, as well as the S&P 500 and the Nasdaq Composite. What can we expect from Palantir next? The second quarter is expected to be another blowout quarter. The company is continuing to reel in work, including contracts with the Navy to improve ship production and fleet readiness and a partnership with Accenture (NYSE: ACN) to develop AI solutions for federal agencies. On the commercial side, Palantir signed a deal with The Nuclear Company to develop and modernize nuclear power plants, as well as an agreement with The Joint Commission to use AI to manage accreditation and certification standards at hospitals and healthcare organizations. Palantir issued guidance for second-quarter revenue of $934 million to $938 million -- the midpoint of that would be a 38% increase from Q2 2024. Its full-year guidance is now in a range from $3.89 billion to $3.902 billion. The main argument for investing in Palantir today, of course, is the valuation. With a trailing price-to-earnings ratio (P/E) of 682 and a forward P/E of 269, Palantir is ungodly expensive. But that's not a deal-breaker for me. I keep remembering that Amazon had a P/E of more than 1,000 back in 2013 before people realized how important cloud computing and its Amazon Web Services platform would be. I think Palantir is like Amazon -- people are just starting to appreciate that Palantir is a transformative company that is changing the world and how businesses and governments operate. And when it reports earnings on Aug. 4, I think you're going to continue to see the stock soar. How to invest in Palantir I would never recommend that someone overinvest in a stock or put their entire nest egg into Palantir. But I do think it's a company that should be part of a portfolio. If you are worried about the inherent volatility that comes with a stock that's growing as quickly as Palantir (and has such a crazy valuation), I recommend using a dollar-cost averaging strategy to establish your position over time. Just be sure never to be overextended on any one stock -- even one as compelling as Palantir. Should you buy stock in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Bank of America is an advertising partner of Motley Fool Money. Patrick Sanders has positions in Nvidia and Palantir Technologies. The Motley Fool has positions in and recommends Accenture Plc, Amazon, Apple, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Palantir Stock Is Up 478% in a Year. Here's Why There's Still More Room to Run. was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) ('Protara' or the 'Company'), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to two newly-hired employees. The Compensation Committee of Protara's Board of Directors approved an aggregate of 14,800 stock option awards and 7,400 RSU awards to two new employees from the Inducement Plan, as inducements material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on August 1, 2025 and have an exercise price of $3.06 per share, Protara's closing trading price on the grant date. Such RSU awards will have a grant date of October 1, 2025. All option awards vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and 1/36th of the underlying shares vesting monthly thereafter over 36 months. All RSU awards vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the grant date. The vesting of all option and RSU awards is subject to the employee's continued service with the company through the applicable vesting dates. About Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara's portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit Company Contact: Justine O'Malley Protara 646-817-2836 Source: Protara TherapeuticsSign in to access your portfolio
Yahoo
an hour ago
- Yahoo
KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MAHWAH, N.J., August 01, 2025--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Adam Kalbermatten, Chief Commercial Officer, pursuant to his previously announced employment agreement with the Company dated as of June 30, 2025. Mr. Kalbermatten was granted nonqualified stock options on August 1, 2025 to purchase 600,000 shares of the Company's common stock at an exercise price of $3.44 per share. In addition, on July 28, 2025, his start date, Mr. Kalbermatten received 300,000 restricted shares of the Company's common stock. Each of these awards are subject to vesting 25% on each anniversary of their grant date, subject to accelerated vesting and the other terms and conditions of the respective award agreements entered into between Mr. Kalbermatten and the Company. The Compensation Committee of the Company's Board of Directors approved the awards as an inducement material to Mr. Kalbermatten's employment in accordance with Nasdaq Listing Rule 5635(c)(4). About KORU Medical Systems KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the "Freedom System") currently includes the Freedom60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit View source version on Contacts Investor Contact: Louisa Smithinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
